Investigation of Ondexxya for treating life-threatening bleeding

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational survey aims to collect data on the safety and effectiveness of Ondexxya, an intravenous injection used to counteract the effects of Factor Xa inhibitors in patients experiencing life-threatening bleeding. The study will monitor the occurrence of adverse drug reactions and assess factors influencing the drug's safety and effectiveness in real-world settings. By gathering this information, the study seeks to enhance understanding of Ondexxya's performance under actual use conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients treated with this drug to neutralize the anticoagulant effect of a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) at onset of a life-threatening bleeding episode or a unarrestable bleeding episode.

Exclusion Criteria:

* N/A

Where it's running

• Research Site
  Aichi, Japan Recruiting
• Research Site
  Aichi, Japan Withdrawn
• Research Site
  Akita, Japan Withdrawn
• Research Site
  Aomori, Japan Withdrawn
• Research Site
  Chiba, Japan Withdrawn
• Research Site
  Chiba, Japan Active not recruiting

+4 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thrombolysis for stroke patients on Factor Xa inhibitors

  This study is testing if a common stroke treatment can safely help patients who have taken certain blood thinners in the last two days.

  Recruiting at 21 sites Phase 3 Oslo University Hospital · Aalborg, Aalborg and 20 other locations · NCT06878066

• Circadian Variation of Anti-Factor Xa in Trauma Patients on LMWH

  This study tests whether anti-Factor Xa levels show a daily rhythm in hospitalized trauma patients receiving LMWH for VTE prevention.

  Recruiting The University of Texas Health Science Center, Houston · Houston, Texas · NCT07856641

• Effects of thickened feeds on swallowing in children with dysphagia

  This study is testing if thickened liquids can help babies with swallowing problems do better when they eat.

  Recruiting Boston Children's Hospital · Boston, Massachusetts · NCT04504227

• Effects of thickened feeds on infants with unexplained life-threatening events

  This study is trying to see if giving thicker feeds to infants who have had scary unexplained events helps improve their health and reduces the need for medical care.

  Recruiting Boston Children's Hospital · Boston, Massachusetts · NCT04477460

• Identifying life-threatening infections linked to immune system errors

  This study is trying to find out how common life-threatening infections are in people with immune system problems to help doctors diagnose and treat them better.

  Recruiting at 6 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna and 5 other locations · NCT06775496

• Understanding what makes care complex for children and young people with serious illnesses

  This project tests how to define and measure complexity in the care of children and young people with life-limiting or lifethreatening conditions, by gathering input from families and health and social care professionals.

  Recruiting at 5 sites King's College London · Birmingham and 4 other locations · NCT07102433

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.